Search

Purpose: To evaluate the effect of simulated gastric acid solution (SGAS) and resin cement composition on the shear bond strength (SBS) of zirconia-based materials with different levels of translucency to composite resin. Materials and Methods: A total of 40 medium-opacity (MO; 3Y-TZP) and 40 medium-translucency (MT; 4Y-PSZ) zirconia slabs were distributed into four groups according to the composition of the resin luting system (MDP free or with MDP [primer + Panavia V5]) and storage method (distilled water or SGAS [5% hydrochloric acid]). Composite resin cylinders were cemented on the zirconia surface and stored for 91 hours. SBS, failure mode, and surface characterization analyses via scanning electron microscopy (SEM) and energy-dispersive spectroscopy (EDS) were performed. SBS data were analyzed using three-way ANOVA and Tukey tests, and failure mode was assessed using one-way ANOVA (P < .05). Results: Storage media (P = .180), resin cement (P = .110), zirconia (P = .404), and their interactions did not affect SBS values. Bond strength ranged from 21.41 to 26.11 MPa. SEM images showed that SGAS modified the surface topography of zirconia and resin cement. The presence of chlorine and silicon (wt%) were higher after SGAS storage than after water storage in both cements used, while barium was higher only for the MDP cement. There was a prevalence of mixed failures for most of the groups. Conclusions: The SBS between both types of zirconia and resin cement was not affected by SGAS, although changes in zirconia topography were observed after SGAS exposure. The presence of MDP in the cement layer had no effect on the SBS challenged by SGAS. [ABSTRACT FROM AUTHOR]

This review outlines the epidemiology, characteristics, risk factors, and prognosis of peritoneal dialysis (PD)-related peritonitis, PD catheter-related infections, and the effects of assisted PD in elderly patients from the Japanese perspective. Based on the literature, the incidence of peritonitis is likely to be higher in elderly patients than in younger patients. The most frequent causative bacteria in elderly patients are Gram-positive bacteria, as in adult PD patients, most commonly due to transcatheter infection. However, elderly patients may have difficulty recognizing cloudy drainage fluid due to decreased visual acuity. Hypokalemia, the use of gastric acid suppressants, prophylactic antibiotic use before endoscopy, biocompatible fluids and hypoalbuminemia considered modifiable risk factors for peritonitis. However, the mechanism by which treatment of hypokalemia prevents peritonitis is unknown. Currently, the relationship between gastric acid suppression therapy and peritonitis in elderly patients is debatable, with no evidence to strongly recommend uniform discontinuation of gastric acid suppression therapy. Exit-site infection (ESI) is a major risk factor for the development of peritonitis, and appropriate prevention and management of ESI may reduce infection-related hospitalizations in PD patients. Currently, no randomized, controlled trials have verified the effectiveness of antibiotic application for ESI in Japan, but results from other countries are awaited. In assisted PD, it is extremely important that family members, caregivers, and nurses who support the procedure receive sufficient education and training from medical professionals familiar with PD. Early detection and treatment of PD-related infections are required because the risk of death increases in elderly patients. [ABSTRACT FROM AUTHOR]

A Raman-active boronate modified surface-enhanced Raman scattering (SERS) microporous array chip based on the enzymatic reaction was constructed for reliable, sensitive, and quantitative monitoring of D-Proline (D-Pro) and D-Alanine (D-Ala) in saliva. Initially, 3-mercaptophenylboronic acid (3-MPBA) was bonded to Au-coated Si nanocrown arrays (Au/SiNCA) via Au–S bonding. Following this, H2O2 obtained from D-amino acid oxidase (DAAO)-specific catalyzed D-amino acids (D-AAs) further reduced 3-MPBA to 3-hydroxythiophenol (3-HTP) with a new Raman peak at 882 cm−1. Meanwhile, the original characteristic peak at 998 cm−1 remained unchanged. Therefore, the I882/I998 ratio increased with increasing content of D-AAs in the sample to be tested, allowing D-AAs to be quantitatively detected. The Au/SiNCA with large-area periodic crown structure prepared provided numerous, uniform "hot spots," and the microporous array chip with 16 detection units was employed as the platform for SERS analysis, realizing high-throughput, high sensitivity, high specificity and high-reliability quantitative detection of D-AAs (D-Pro and D-Ala). The limits of detection (LOD) were down to 10.1 µM and 13.7 µM throughout the linear range of 20–500 µM. The good results of the saliva detection suggested that this SERS sensor could rapidly differentiate between early-stage gastric cancer patients and healthy individuals. [ABSTRACT FROM AUTHOR]

Purpose: Laryngopharyngeal reflux disease (LPRD) is mainly treated with proton pump inhibitors (PPI) such as esomeprazole, which have shortcomings like delayed absorption and increased osteoporosis. Fexuprazan is a novel potent potassium-competitive acid blocker that inhibits gastric acid secretion with rapid onset and long duration of action. To assess the efficacy and safety of fexuprazan compared to esomeprazole in patients with LPRD. Methods: This prospective, randomized, double-blinded, multicenter, active-controlled trial was conducted in nine otolaryngologic clinics. Patients with reflux symptom index (RSI) ≥ 13 and reflux finding score (RFS) ≥ 7 were randomly assigned to the fexuprazan or esomeprazole groups, and received fexuprazan 40-mg or esomeprazole 40-mg once daily for 8 weeks. The outcomes were (1) mean change, change rate, and valid rate in RSI, RFS, and LPR-related questionnaires; and (2) adverse events. Results: A total of 136 patients (fexuprazan n = 68, esomeprazole n = 68) were followed up for ≥ 1 month. Each parameter significantly improved after 4 and 8 weeks in each group, with no significant differences between the two groups. For those with severe symptoms (RSI ≥ 18), the fexuprazan group (n = 32) showed more improvement in the mean change and change rate in the RSI than esomeprazole group (n = 31) after 4 weeks (p =.036 and.045, respectively). This phenomenon was especially observed in hoarseness and troublesome cough. Conclusion: Fexuprazan improved symptoms and signs without no serious adverse events in patients with LPRD. In patients with severe symptoms, fexuprazan resulted in a faster symptom improvement than PPI. Trial registration: KCT0007251, https://cris.nih.go.kr/cris/search/detailSearch.do?seq=22100. [ABSTRACT FROM AUTHOR]

Background/Aims: Long‐term acid suppression with proton pump inhibitors (PPI) leads to hypochlorhydria and facilitates the growth of bacterial flora in the small intestine. Novel acid‐suppressants called potassium‐competitive acid blockers (P‐CABs) seem to be superior to PPIs. However, data on the risk of small intestinal bacterial overgrowth (SIBO) in patients taking P‐CABs are limited. Method: We retrospectively analyzed a consecutive series of patients with long‐term acid‐suppressant (PPIs or P‐CABs) use for gastroesophageal reflux disease or nonsteroidal anti‐inflammatory drug (NSAID)‐induced gastropathy. All of them underwent endoscopic examinations and Helicobacter pylori testing and took PPIs or P‐CABs for at least 3 months. Glucose hydrogen breath tests (GBT) were performed to check for SIBO, and newly developed SIBO‐related symptoms including bloating, postprandial discomfort, diarrheas, and constipation, were evaluated. Results: A total of 142 patients were enrolled. Six patients were excluded due to equivocal Helicobacter pylori infection results. The frequency of positive GBTs was 31.7% (25/79) for PPI and 22.8% (13/57) for P‐CAB use (p = 0.15). Regarding GBT positivity, age‐related factor was found to be significant in multivariate analysis (p = 0.02). The results of multivariate analysis in cases of SIBO‐related symptoms showed that GBT positivity and PPI use were significant (p < 0.01). Conclusion: Long‐term use of gastric acid suppressants resulted in positive GBT in approximately 30% of patients, and the risk was particularly high in elderly patients. The occurrence of SIBO‐related symptoms was significant in long‐term use of PPIs and in patients with positive GBT. [ABSTRACT FROM AUTHOR]

ABSTRACT Metal–organic framework (MOF) is a porous material composed of metal ions/clusters and organic ligands. It has attracted much attention due to its high specific surface area, good biocompatibility, chemical modifiability, and diversity of components. Among many MOFs, zirconium‐based MOFs are particularly suitable for biological applications due to their optimal stability and low toxicity to hydrolysis. However, due to the weak coordination bonds between many metal clusters and organic ligands, most MOFs are prone to collapse in acidic environments, and the stability of MOFs as drug carriers cannot be guaranteed so that they cannot be widely used as oral drug carriers. This study synthesized the three MOFs using metal Zr ion clusters as the center and different nitrogen‐containing organic ligands, which are stable in gastric acid, namely, UiO‐66‐PDC, UiO‐66‐NH2, and UiO‐66‐NO2. The anionic drug loxoprofen (LOX) was loaded and characterized using scanning electron microscopy, infrared spectroscopy, thermogravimetric analysis, differential scanning calorimetry, and x‐ray diffraction. The adsorption and release behaviors of LOX and the three MOFs were studied from the molecular point of view by computer simulation. A series of behaviors and mechanisms of pH‐responsive nitrogen‐containing MOFs as oral drug carriers were further explored through rat pharmacokinetic experiments, the everted gut sac experiments, and intestinal absorption mechanism experiments. The experimental results show that there is a strong electrostatic interaction between anionic drug LOX and UiO‐66‐PDC under simulated gastric acid environment, which prolongs the half‐life of the drug, proving that LOX@UiO‐66‐PDC is a promising new oral drug delivery system. [ABSTRACT FROM AUTHOR]

Simple Summary: Gastric disease in horses is common and has significant effects on welfare and performance. Gastrin is a hormone involved in the control of gastric acid secretion. Investigations into the effect of gastrin on gastric disease are important for further understanding of the disease and its treatment. However, there has only been one assay validated for the measurement of gastrin in horses. This study aimed to compare the performance of two commercially available, non-validated assays to the previously validated assay. The results showed poor performance of both non-validated assays, and do not support their use for gastrin measurement in future research. Gastrin is an important hormone involved in gastric acid secretion. Despite its importance, validated methods other than radioimmunoassay (RIA) to assess serum gastrin concentrations in horses are lacking. This study aims to determine the agreement between ELISA and RIA in quantifying equine serum gastrin concentrations. Serum gastrin concentrations were quantified using two ELISA kits and RIA. Samples (196) from 14 horses at different time points were analyzed using one ELISA kit and RIA, selected samples (7) were analyzed using a second ELISA kit, and the correlation between methods was calculated. The level of agreement was analyzed by Bland-Altman analysis and differences between ELISA and RIA were plotted against averages for each sample. The Pearson correlation between gastrin concentrations measured by ELISA and the RIA was 0.27 and −0.32 for ELISA kit 1 and kit 2, respectively. Mean bias (ELISA-RIA) was 198.40 pg/mL (95% CI: −142.95–539.76) and −17.90 pg/mL (95% CI: −89.98–54.19) for ELISA kit 1 and kit 2, respectively. Measurements of horse gastrin by both ELISA methods were highly variable, with an unacceptable correlation to the reference method, RIA. Using non-validated ELISA methods to quantify horse gastrin cannot be recommended. [ABSTRACT FROM AUTHOR]

In patients with abdominal or pelvic tumors, radiotherapy can result in radiation-induced intestinal injury (RIII), a potentially severe complication for which there are few effective therapeutic options. Sitagliptin (SI) is an oral hypoglycemic drug that exhibits antiapoptotic, antioxidant, and anti-inflammatory activity, but how it influences RIII-associated outcomes has yet to be established. In this study, a pH-responsive metal-organic framework-based nanoparticle platform was developed for the delivery of SI (SI@ZIF-8@MS NP). These NPs incorporated mPEG-b-PLLA (MS) as an agent capable of resisting the effects of gastric acid, and are capable of releasing Zn2+ ions. MS was able to effectively shield these SI@ZIF-8 NPs from rapid degradation when exposed to an acidic environment, enabling the subsequent release of SI and Zn2+ within the intestinal fluid. Notably, SI@ZIF-8@MS treatment was able to mitigate radiation-induced intestinal dysbiosis in these mice. restored radiation-induced changes in bacterial composition. In summary, these data demonstrate the ability of SI@ZIF-8@MS to protect against WAI-induced intestinal damage in mice, suggesting that these NPs represent a multimodal targeted therapy that can effectively be used in the prevention or treatment of RIII. [ABSTRACT FROM AUTHOR]

BACKGROUND AND OBJECTIVE: Few studies have explored the relationship between social drivers of health and pediatric low-value care (LVC). We assessed the relationship between Childhood Opportunity Index (COI) 2.0 and LVC in children's hospitals. METHODS: We applied the Pediatric Health Information System LVC Calculator to emergency and inpatient encounters from July 2021 through June 2022. Proportions with LVC in highest (greatest opportunity) and lowest COI quintiles were compared. Generalized estimating equation logistic regression models were used to analyze LVC trends across COI quintiles. RESULTS: 842 463 encounters were eligible for 20 LVC measures. Across all measures, odds of LVC increased across increasing COI quintiles (adjusted odds ratio [OR] 1.06, 95% confidence interval [CI] 1.03-1.08). For 12 measures, LVC was proportionally more common in highest versus lowest COI quintile, whereas the reverse was true for 4. Regression modeling revealed increasing LVC as COI increased across all quintiles for 10 measures; gastric acid suppression for infants had the strongest association (OR 1.22, 95% CI 1.17-1.27). Three measures revealed decreasing LVC across increasing COI quintiles; Group A streptococcal testing among children <3 years revealed the lowest OR (0.85, 95% CI 0.73-0.99). The absolute volume of LVC delivered was greatest among low COI quintiles for most measures. CONCLUSIONS: Likelihood of LVC increased across COI quintiles for 10 of 20 measures, whereas 3 measures revealed reverse trends. High volumes of LVC across quintiles support a need for broad de-implementation efforts; measures with greater impact on children with lower opportunity warrant prioritized efforts. [ABSTRACT FROM AUTHOR]

In this study, alkali-soluble polysaccharide from Manilkara zapota (MZAP) was extracted and polysaccharide-iron complexes MZAP-Fe (III) was synthesized. Structural characterization, antioxidant and digestive properties were used to evaluate the feasibility of MZAP-Fe (III) as an iron supplement. The results showed that when the reaction temperature was 70 ℃, the pH was 9 and the addition of sodium citrate was 0.025 g, MZAP- Fe (Ⅲ) had the highest iron content (14.68 %) and its average molecular weight increased compared to MZAP. The UV and FT-IR results indicated that MZAP- Fe (Ⅲ) was formed by the carboxyl and hydroxyl groups in MZAP with the iron group to form Fe-O bonds. MZAP-Fe (III) maintained high thermal stability over the temperature range of 20°C to 450℃. When the concentration of MZAP- Fe (Ⅲ) was 1.0 mg/mL, hydroxyl radical-scavenging activity and DPPH radical scavenging activity reached 57.03 % and 82.21 %, respectively, and both were significantly higher than the antioxidant activity of MZAP. Moreover, in the simulating human digestion, MZAP- Fe (Ⅲ) was more stable than FeSO 4 and less likely to be destroyed by stomach acid. The present study demonstrated the potential of MZAP-Fe (III) as a novel iron supplement. [Display omitted] • MZAP-Fe(Ⅲ) was successfully synthesized with MZAP. • MZAP-Fe (III) possessed superior antioxidant activity than MZAP. • MZAP-Fe (III) could be better utilized in simulated in vitro digestion. [ABSTRACT FROM AUTHOR]

Inflammatory bowel disease (IBD) is inflammatory intestinal disorders associated with dysregulated gut microbiota. Bacteriotherapy that leverages bacteria as therapeutics has shown tremendous promise in resolving gut dysbiosis and reducing inflammatory mediators to treat IBD. Orally delivered probiotics, such as Escherichia coli Nissle 1917 (EcN), can produce beneficial ingredients, competitively inhibit the proliferation of pathogens, and promote the restoration of gut microbiome homeostasis. However, environmental stresses (such as gastric acids) in the gastrointestinal (GI) tract pose an enormous challenge to the probiotics following oral administration, leading to decreases in viability and activity of probiotics. Meanwhile, the inferior mucoadhesive capability of probiotics results in low colonization efficacy, further compromising their therapeutic effect. Coating probiotics with functional biomaterials may protect them from elimination and prolong their retention in the GI tract. Here, we developed a facile double-layer electrostatic assembly technique to encapsulate EcN bacteria in protective layers of mucoadhesive chitosan (CS) and immunomodulatory hyaluronic acid (HA) to generate HA-CS-EcN. These biomaterials confer the coated EcN resistance to environmental assault and enhanced mucoadhesion in the GI tract. The probiotics equipped with the multifunctional shield can thus suppress inflammation and reshape the intestinal microenvironment to enhance therapeutic efficacy for the prevention and treatment of IBD. Collectively, this study presents a novel probiotic coating strategy to augment the outcome of bacteriotherapy to combat IBD. [ABSTRACT FROM AUTHOR]

Proton pump inhibitors (PPIs) are some of the most commonly prescribed drugs worldwide, but there are increasing concerns about digestive complications linked to PPIs. Next-generation sequencing studies have suggested that PPIs can significantly affect the composition of the gut microbiota, which in turn may substantially contribute to the development of these complications. Recently, emerging evidence has suggested that the translocation of oral microbes into the gut may be the primary mechanism underlying the alterations in the gut microbiota induced by PPIs in the presence of gastric acid suppression and impaired oral–gut barrier function. Moreover, the significance of oral–gut microbial translocation in health and disease conditions has gained increasing recognition. Consequently, it is imperative to enhance our understanding of the functions of the oral–gut microbiota axis in digestive disorders associated with PPI therapies. This review aims to summarize current research findings and further elucidate the contribution of the oral–gut microbiota to the pathogenesis of PPI-related digestive diseases. We aim to provide a theoretical foundation for future therapeutic and preventive strategies targeting PPI-related digestive complications through modulation of the oral–gut microbiota. [ABSTRACT FROM AUTHOR]

This study aimed to investigate the effect of acidic media storage (gastric acid and Coca-Cola) on the mechanical properties of CAD/CAM materials. Three types of materials were tested: a polymer-infiltrated ceramic network (PICN) (Vita Enamic (En), VITA Zahnfabrik, Germany), a resin composite block (RCB) (Cerasmart (Cs), GC Corp, Japan), and a conventional resin-based composite (Gradia direct (Gr), GC Corp, Japan), which was used as a control. Beam-shaped specimens of each material, with dimensions of 16 mm × 4 mm × 1.5 mm, were prepared (90 in total). The specimens were divided into subgroups (10 each) and stored for 96 h in either gastric acid, Coca-Cola, or distilled water. Flexural strength and elastic modulus were evaluated using a three-point flexural strength test with acoustic emission (AE) monitoring. Vickers microhardness was measured before and after storage in gastric acid and Coca-Cola. Data were statistically analysed using two-way and one-way ANOVA, the Tukey's post hoc, and independent t-test at a significance level of 0.05. The results showed that Cs and En maintained their flexural strength and elastic modulus after acidic media exposure, while Gr experienced a significant decrease in flexural strength following gastric acid storage (p < 0.01). Initial crack detection was not possible using the AE system, impacting the determination of flexural strength. Exposure to acidic media decreased all materials' microhardness, with Gr showing the most notable reduction (p < 0.0001). Gastric acid had a greater impact on the microhardness of all tested materials compared to Coca-Cola (p < 0.0001). In conclusion, storage in erosive media did not notably affect the flexural strength or elastic modulus of CAD/CAM composites but it did affect hardness. CAD/CAM composite blocks demonstrated superior mechanical properties compared to the conventional composite. [ABSTRACT FROM AUTHOR]

Buffering of stomach acid by antacids is a well-established symptomatic therapy for heartburn. In addition, preparations from prickly pear (Opuntia ficus-indica) have been shown to reduce tissue damage in experimental gastritis models and to attenuate gastrointestinal discomfort in patients. Both active principles have been included in a fixed-combination product for symptomatic treatment of heartburn containing carbonate antacids (CaCO3 and MgCO3) and an extract from Opuntia ficus-indica cladodes. The aim of the study was to characterize the acid neutralization and esophageal cell protective activities of the product and its individual active ingredients in a set of in vitro assays. Acid neutralization was assessed in a simulated stomach model. Protective activity of individual constituents and in combination was analyzed in an esophageal cell line (COLO-680 N) exposed to low pH and deoxycholic acid to simulate acidic and non-acidic reflux challenge. The combination product protected cells against low pH mediated cytotoxicity via acid neutralization by carbonates. Opuntia extract itself and the combination product attenuated bile acid-induced cell irritation as measured by reduced release of proinflammatory interleukin-6 and -8. In conclusion, addition of Opuntia extract to a mineral antacid provides dual protection against acidic and non-acidic simulated reflux challenge. [ABSTRACT FROM AUTHOR]

Effective suppression of gastric acid secretion promotes healing of erosive esophagitis. Treatment guidelines recommend proton pump inhibitors (PPIs) and histamine H2–receptor antagonists (H2RAs). Emerging evidence also supports potassium‐competitive acid blockers (P‐CABs). The aim was to construct a mathematical model to examine the relationship between pH holding time ratios (HTRs) and erosive esophagitis healing rates with H2RAs, PPIs and P‐CABs. By literature search, we identified studies of H2RAs, PPIs or P‐CABs that reported mean pH >4 HTRs at steady state (days 5–8) and erosive esophagitis healing rates after 4 and/or 8 weeks. We aggregated treatments by drug class and developed a non‐linear, mixed‐effects model to explore the relationship between pH >4 HTRs and healing rates. The pH dataset included 82 studies (4297 participants; 201 dosage arms); healing rate data came from 103 studies (43,417 patients; 196 treatment arms). P‐CABs achieved the longest periods with intragastric pH >4, and the highest healing rates after 4 and 8 weeks. The predicted probabilities of achieving ≥90% healing rates at 8 weeks were 74.1% for P‐CABs, 17.3% for PPIs and 0% for H2RAs. P‐CABs provide the longest duration with intragastric pH >4 and, accordingly, the highest healing rates of erosive esophagitis. [ABSTRACT FROM AUTHOR]

Gastritis is one of the most commonly encountered digestive diseases, especially in Indonesia, with a relatively high prevalence. This condition is characterized by inflammation of the gastric mucosa, often causing pain in the epigastric area. According to various studies, this pain is caused by an increase in stomach acid, which triggers inflammation and stimulates nociceptors, leading to discomfort. To address this issue, one non-pharmacological approach that can be employed is deep breathing relaxation therapy. This therapy helps patients reduce pain by improving lung ventilation, reducing muscle tension, and stabilizing other bodily functions such as heart rate and blood pressure. Several previous studies have also shown that this technique is effective in reducing pain intensity in gastritis patients, speeding up the healing process, and enhancing patient comfort. This study aims to explore the implementation of deep breathing relaxation techniques in reducing pain intensity in gastritis patients. It is a descriptive study with a case study approach. The sample used in this research consists of two respondents, who are gastritis patients hospitalized at Vita Insani Hospital in Pematangsiantar. The evaluation results showed a decrease in pain intensity, from a pain scale of 4 (moderate) to 0 (none) in patient I, and from a pain scale of 6 (moderate) to 0 (no pain) in patient II. Thus, it can be concluded that the deep breathing relaxation technique is effective in reducing pain intensity in gastritis patients. [ABSTRACT FROM AUTHOR]

Background: Perineuriomas of the gastrointestinal tract are benign neoplasms that commonly develop in the distal colon and are identified during screening colonoscopy; however, perineuriomas of the stomach are exceedingly rare and less frequently identified. Differentiating gastric perineuriomas from other more serious gastric neoplasms is critical to avoid unnecessarily aggressive treatments. Thus far, only six patients with gastric perineurioma have been described, and the molecular characterization of this entity is still lacking. Case Presentation: We report a 52-year-old woman who presented with abdominal pain and gastric acid reflux and was found to have a 1.5 cm subepithelial gastric neoplasm composed of bland spindle cells displacing the gastric glands with no cytologic atypia or mitotic activity, suggesting a benign spindle cell neoplasm. Immunohistochemical analysis showed reactivity for perineurial markers glucose transporter-1 and epithelial membrane antigen, consistent with benign gastric perineurioma. DNA extracted from the tissue was used for a capture-based target sequence enrichment panel followed by Illumina next-generation sequencing and targeted bioinformatic analysis for oncogenic alterations within defined disease-associated target regions. No sequence variants in the BRAF gene were identified. Conclusions: This rare case of gastric perineurioma helps solidify our understanding of how to discern various types of gastric neoplasms through traditional laboratory analysis alongside genetic sequencing approaches. Although extremely rare, gastric perineurioma should be kept in the differential diagnosis when assessing spindle cell gastric tumors to avoid unnecessary therapies, and physicians should understand the molecular characteristics of benign versus malignant tumors. [ABSTRACT FROM AUTHOR]

Aluminum phosphide (AlP) is the main component of rice tablets (a pesticide), which produces phosphine gas (PH3) when exposed to stomach acid. The most important symptoms of PH3 toxicity include, lethargy, tachycardia, hypotension, and cardiac shock. It was shown that Iodine can chemically react with PH3, and the purpose of this study is to investigate the protective effects of Lugol solution in poisoning with rice tablets. Five doses (12, 15, 21, 23, and 25 mg/kg) of AlP were selected, for calculating its lethal dose (LD50). Then, the rats were divided into 4 groups: AlP, Lugol, AlP + Lugol, and Almond oil (as a control). After 4 h, the blood pressure and electrocardiogram (ECG) were recorded, and blood samples were obtained for biochemical tests, then liver, lung, kidney, heart, and brain tissues were removed for histopathological examination. The results of the blood pressure showed no significant changes (P > 0.05). In ECG, the PR interval showed a significant decrease in the AlP + Lugol group (P < 0.05). In biochemical tests, LDH, Ca2+, Creatinine, ALP, Mg2+, and K+ represented significant decreases in AlP + Lugol compared to the AlP group (P < 0.05). Also, the administration of Lugol's solution to AlP-poisoned rats resulted in a significant decrease in malondialdehyde levels and a significant increase in catalase activity (P < 0.05). Histopathological evaluation indicates that Lugol improves changes in the lungs, kidneys, brain, and heart. Our results showed that the Lugol solution could reduce tissue damage and oxidative stress in AlP-poisoned rats. We assume that the positive effects of Lugol on pulmonary and cardiac tissues are due to its ability to react directly with PH3. [ABSTRACT FROM AUTHOR]

Durio kutejensis, commonly known as Lai durian, has a unique characteristics of a creamy texture and a combination of sweet and bitter tastes. This study aimed to isolate and screen yeast from fruits as a potential probiotic agent. The tests consisted of tolerance to bile salt and gastric acid at pH 2, antibacterial activity against Listeria monocytogenes and Salmonella enteriditis, and hemolytic activity on blood agar medium. The results showed that 40 yeasts isolated from Lai durian fruit and 34 of these isolates grew on YMA medium. The two isolates showed high significance in the probiotic tests. These two isolates were able to grow on bile salt up to a concentration of 2% and gastric acid for up to 6 h, with survival rates of 99.06% and 100%, respectively. Two isolates were identified as Pichia kudriavzevii UNJCC Y-137 and Candida tropicalis UN-JCC Y-140 Therefore, these two yeast isolates can be used as potential probiotic agents. [ABSTRACT FROM AUTHOR]

Introduction and Background: Diabetes is a chronic metabolic disease characterized by elevated blood glucose levels and is one of the main global health concerns. Synthetic sugar substrate has many side effects such as leukemia, bladder cancer, hepatotoxicity, breast cancer, headache, and brain toxicity. The WHO and FDA has recently banned some of the synthetic sugar alternatives due to their carcinogenic effects. Objective and Methodology: Therefore, the main objective of the current study was to investigate the safety and binding affinity of Stevioside with Glucose Transpoter-4 (GLUT-4), Akt, Insulin Receptor (IR) and Insulin Receptor Substrate-1 (IRS-1) to confirmed that Stevioside is one the potent natural sweetener/drug for diabetes. This study delves into the molecular interaction between Stevioside and key diabetic proteins: GLUT-4, Akt, IR and IRS-1. A precise molecular docking approach was used to simulate the binding affinity of Stevioside to these proteins. The pharmacokinetic properties of the molecule should be taken into consideration as important variables throughout the virtual screening process. Results: The result of active site analysis of GLUT-4, Akt, IR and IRS-1 showed a zone of 2158.359 Ų, 579.259 Ų, 762.651 Ų, and 152.167 Ų and a volume of 2765.094 ų, 355.567 ų, 686.806 ų, and 116.874 ų, respectively. Docking analysis of the Stevioside compound showed the highest docking energy with scores of -9.9 with GLUT-4, -6.7 with Akt, -8.0 with IR and -8.8 with IRS-1. Studies indicated that it remains undigested by stomach acids and enzymes and is not absorbed in the upper small intestine. Further, tests revealed no hepatotoxicity, AMES toxicity, or skin sensitivity, making it a promising candidate for safe consumption as drug metabolism. Conclusion and Recommendations: Instead of other sugar alternatives, Stevioside will help diabetic patients with a lower chance of infections, lowered blood pressure/blood sugar, and increased glucose uptake in diabetic muscles. Stevioside is a natural sweetener, and the current study recommends its usage in various dietary products for diabetic patients. [ABSTRACT FROM AUTHOR]

Enteric pathogens navigate distinct regional microenvironments within the intestine that cue important adaptive behaviors. We investigated the response of Citrobacter rodentium, a model of human pathogenic Escherichia coli infection in mice, to regional gastrointestinal pH. We found that small intestinal pH (4.4–4.8) triggered virulence gene expression and altered cell morphology, supporting initial intestinal attachment, while higher pH, representative of C. rodentium's replicative niches further along the murine intestine, supported pathogen growth. Gastric pH, a key barrier to intestinal colonization, caused significant accumulation of intra-bacterial reactive oxygen species (ROS), inhibiting growth of C. rodentium and related human pathogens. Within-host adaptation increased gastric acid survival, which may be due to a robust acid tolerance response (ATR) induced at colonic pH. However, the intestinal environment changes throughout the course of infection. We found that murine gastric pH decreases postinfection, corresponding to increased serum gastrin levels and altered host expression of acid secretion-related genes. Similar responses following Salmonella infection may indicate a protective host response to limit further pathogen ingestion. Together, we highlight interlinked bacterial and host adaptive pH responses as an important component of host–pathogen coevolution. Enteric pathogens navigate distinct regional micro-environments along the intestinal tract. This study shows that intraluminal intestinal pH is an important spatial driver of virulence and adaptive behavior during C. rodentium infection, and is manipulated by the host in response to pathogen invasion. [ABSTRACT FROM AUTHOR]

The lysosomal Ca2+ channel TRPML1 was found to be responsible for gastric acid secretion in murine gastric parietal cells by inducing the trafficking of H+/K+-ATPase containing tubulovesicles to the apical membrane. Therefore, we hypothesized a similar role of TRPML1 in regulating proton secretion in the immortalized human parietal cell line HGT-1. The primary focus was to investigate the involvement of TRPML1 in proton secretion using the known synthetic agonists ML-SA1 and ML-SA5 and the antagonist ML-SI3 and, furthermore, to identify food-derived compounds that target the channel. Proton secretion stimulated by ML-SA1 was reduced by 122.2 ± 22.7% by the antagonist ML-SI3. The steroid hormone 17β-estradiol, present in animal-derived foods, diminished the proton secretory effect of ML-SA1 by 63.4 ± 14.5%. We also demonstrated a reduction in the proton secretory effects of ML-SA1 and ML-SA5 on TRPML1 knock-down cells. The food-derived compounds sulforaphane and trehalose promoted proton secretion in HGT-1 cells but may act independently of TRPML1. Also, histamine- and caffeine-induced proton secretion were affected by neither the TRPML1 antagonist ML-SI3 nor the TRPML1 knock-down. In summary, the results obtained suggest that the activation of TRPML1 promotes proton secretion in HGT-1 cells, but the channel may not participate in canonical signaling pathways. [ABSTRACT FROM AUTHOR]

Background: Increased eradication of Helicobacter pylori decreases the incidence of gastric cancer. Vonoprazan is a potassium-competitive acid blocker (PCAB) with a stronger acid production suppression effect than proton pump inhibitors (PPI). Vonoprazan has been recognized as a therapy for gastric acid reflux disease since 2015 in Japan, but the comparison of the effectiveness of PCAB first-line therapy with PPI for adult patients with H. pylori infection is still controversial. Method: A literature search was carried out on three databases: Pubmed, Cochrane, and Scopus on March 30th 2023, using keywords vonoprazan, potassium competitive acid blocker (PCAB), proton pump inhibitor, and H. pylori. There were 7 studies on Pubmed, 26 studies on Cochrane, and 144 studies on Scopus. Critical screening was conducted using the Oxford Centre for Evidence-Based Medicine for systematic reviews and randomized controlled trials. Results: Based on screening of inclusion and exclusion criteria, one study met the criteria. The intention to treat analysis (ITT) showed eradication of H. pylori in the combination of three therapies with PCAB vs PPI of 91.81% vs 75.5% (1,18 [1.08−1.28], p<0,0001), no heterogeneity found (I2 = 43%). Analysis per protocol showed PCAB versus PPI eradications of 92.99% vs 78.57% (1,13 [1,02−1,26], p = 0.02), heterogeneity obtained (I 2 = 75%). Conclusion: Generally, PCAB has better eradication than PPI as first-line therapy for adult patients with H. pylori infection. [ABSTRACT FROM AUTHOR]

Background: Bile acid reflux stands out as a notable risk factor for dyspepsia. Among patients with bile acid reflux, prevalent endoscopic observations encompass mucosal erythema, the detection of bile acid on the mucosa, erosion, hyperugosity, and gastric mucosal atrophy. This study aimed to elucidate the association between bile acid levels in gastric fluid and the degree of gastric mucosal damage. Methods: A cross-sectional investigation involved dyspeptic patients who underwent endoscopy at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital. Bile acid analysis was conducted through the enzymatic calorimetric method, while assessment of mucosal damage relied on the Lanza score, evaluated independently by two observers. Mucosal damage severity was categorized as either mild (score 0-2) or severe (score 3-5). Cohen’s kappa analysis, bivariate, and logistic regression analysis was empoyed. Results: Among the 99 subjects involved, 58.6% were male. H. pylori antibodies were detected in 21% of the participants, while 48% exhibited a pH below 2.77.Additionally, 48% reported a history of NSAID consumption. The mean bile acid level in gastric fluid was 156.07 μmol/L, with a median of 170.09 μmol/L (categorized as high if ≥170.09 μmol/L, and low if <170.09 μmol/L). During endoscopic examination, mild mucosal damage was observed in 61%, and severe damage in 39% (kappa 1, P<0.001). A statistically significant relationship between gastric fluid bile acid levels and mucosal damage was evident (P<0.05). Conclusion: This study concludes that there was a relationship between the level of bile acid in gastric fluid and the degree of mucosal damage. [ABSTRACT FROM AUTHOR]

Objective Little is known about thyroid cancer survivors' risk of chronic conditions. We, therefore, investigated the prevalence of drugs used for chronic conditions among thyroid cancer patients using population-wide register data. Methods We linked data from the Cancer Registry of Norway to the Norwegian Prescription Database and other databases for a study population of 3.52 million individuals, including 3486 individuals with thyroid cancer diagnosed during 2005-2019. Prevalence ratios (PRs) with 95% CIs of reimbursed prescribed drugs in thyroid cancer patients up to 15 years after thyroid cancer diagnosis were estimated by log-binomial regression, with the cancer-free population as reference. Results Individuals (both males and females) with thyroid cancer had higher use of drugs for several chronic conditions in the years after diagnosis; eg, 5 years after thyroid cancer diagnosis, there was elevated use of drugs for hypoparathyroidism (PRmales = 35.4, 95% CI, 25.2-49.7; PRfemales = 42.8, 95% CI, 34.2-53.6), hypertension (PRfemales = 1.20, 95% CI, 1.12-1.28), anxiety and tension (PRmales = 4.01, 95% CI, 1.80-8.92; PRfemales = 2.01, 95% CI, 1.15-3.52), gastric acid disorders (PRmales = 1.52, 95% CI, 1.22-1.91; PRfemales = 1.45, 95% CI, 1.27-1.66), and pain (PRmales = 1.48, 95% CI, 1.11-1.97; PRfemales = 1.24, 95% CI, 1.08-1.42) as compared with the cancer-free population. In addition, males with thyroid cancer had long-term elevated use of drugs for depression (eg, year 10+, PRmales = 1.66, 95% CI, 1.06-2.59). Individuals with thyroid cancer also had higher use of drugs for several conditions prior to the thyroid cancer diagnosis, eg, hypertension, gastric acid disorders, and pain. Conclusions Individuals diagnosed with thyroid cancer had elevated long-term use of drugs for several chronic conditions, as compared with the cancer-free population. [ABSTRACT FROM AUTHOR]

The absorption of dietary phosphorus typically begins with the digestive phase, where various chemical processes take place. These include the solubilization of calcium phosphates by gastric acid in the stomach, as well as the enzymatic breakdown of various organic phosphorus compounds within the intestinal lumen. Enhancing the digestive phase can be achieved by pre-digesting diets or designing them to be readily digestible, which can be especially advantageous for fish with limited digestive capabilities. This improvement may involve supplementing the diets with phytase and organic acids, fermenting feed ingredients, and selecting highly digestible ingredients. Following the digestive phase, solubilized inorganic phosphates and small organic phosphates are absorbed across the intestinal epithelium. This absorptive process is governed by numerous bodily mechanisms that are not easily altered or enhanced. Nonetheless, comprehending these absorptive mechanisms of dietary phosphorus may pave the way for the development of novel methods to increase dietary phosphorus absorption. [ABSTRACT FROM AUTHOR]

Summary: The human gastrointestinal tract hosts a diverse and intricate microbial community, a pivotal contributor to human well‐being. An effective strategy for exploring the diversity and potential probiotic attributes of Bacillus species is to isolate them from faecal samples. In this investigation, we scrutinised the in vitro probiotic characteristics of Bacillus coagulans VHBAX‐04, an isolate derived from human faeces. These attributes encompassed acid and gastric juice tolerance, resistance to bile salts and intestinal juice, adhesion capabilities, safety profile, antibiotic resistance pattern, the absence of toxin genes, and antimicrobial efficacy. Furthermore, we conducted in silico analyses to evaluate its probiotic potential. The notable absence of genes associated with mucin degradation, red blood cell lysis, gelatin hydrolysis, or toxin production in B. coagulans VHBAX‐04 certifies its safety as a probiotic. Additionally, the distinct antibiotic resistance pattern of strain VHBAX‐04 suggests its potential for co‐administration with antibiotics. In conclusion, this study underscores the suitability of B. coagulans VHBAX‐04 as a viable probiotic option. Isolation and Evaluation of Bacillus coagulans WBX04: A Probiotic Strain from Human Feces Studied through 16S rRNA Sequencing and In Vitro Tests. [ABSTRACT FROM AUTHOR]

Introduction: Postpartum depression is one of the most common non‐obstetric postnatal complications. As the microbiome (and gut–brain axis) as well as inflammation may be involved in the mechanism, we aimed to assess if antibiotic or gastric acid inhibition use during pregnancy affects the risk of postpartum depression (clinical diagnosis and/or antidepressant use up to 1 year after childbirth). Material and Methods: This population‐based cohort study used first singleton pregnancy resulting in a live birth in Sweden from 2006 to 2016. Women with history of depression were excluded. Multivariable logistic regression models were used to assess the impact of antibiotics and gastric acid inhibitors and other risk factors, presented as odds ratios (ORs) with 95% confidence intervals (CI). Results: Overall, 29% of all 10 666 women with postpartum depression were exposed to antibiotics and 6.2% to gastric acid inhibitors, compared to, respectively, 21% and 3.2% of 613 205 women without postpartum depression. Antibiotic use during pregnancy was associated with postpartum depression (OR 1.43, 95% CI 1.37–1.49), particularly for quinolones and other antibacterials (including nitroimidazole derivatives). Gastric acid inhibition was associated with an even higher risk than antibiotics (OR 2.04, 95% CI 1.88–2.21). Both antibiotics and gastric acid inhibitors suggested higher risk with increased dose in a dose–response analysis. Conclusions: The use of antibiotics and gastric acid inhibition drugs during pregnancy appeared to be associated with a higher risk of postpartum depression. However, it is important to consider that other predisposing factors could contribute to this increased risk, even after excluding individuals with a history of depression. [ABSTRACT FROM AUTHOR]

We conducted this three‐part study in healthy subjects to investigate the pharmacokinetics of tasurgratinib (orally available selective inhibitor of fibroblast growth factor receptor 1–3) and M2 (its major metabolite) under different conditions. In Part A, subjects received tasurgratinib 35 mg either fed with a high‐fat meal or fasted. In Parts B and C, subjects received tasurgratinib 35 mg alone or with either rabeprazole (acid‐reducing agent) 20 mg (Part B) or rifampin (strong CYP3A inducer) 600 mg (Part C). Primary endpoints were maximum concentration (Cmax), and areas under the plasma concentration–time curve to time of last quantifiable concentration (AUC(0–t)) and extrapolated to infinite time (AUC(0–inf)). Forty‐two subjects were enrolled, 14 each into Parts A, B, and C. In Part A, administration of tasurgratinib with a high‐fat meal resulted in 33% reduction in Cmax and ∼23% reduction in AUC(0–t) and AUC(0–inf) of tasurgratinib, and 47% reduction in Cmax with ∼30% reduction in AUC(0–t) and AUC(0–inf) of M2. In Part B, co‐administration of rabeprazole at steady state resulted in no/weak interaction with tasurgratinib (∼8% increase in AUC(0–t) and AUC(0–inf) without an effect on Cmax) and M2 (∼18% increase in AUC(0–t) and AUC(0–inf) without an effect on Cmax). In Part C, co‐administration of rifampin at steady state resulted in a weak interaction with tasurgratinib (∼16% reduction in AUC(0–t) and AUC(0–inf)) and M2 (∼12% reduction in AUC(0‐t) and AUC(0‐inf)). Administration of tasurgratinib with a high‐fat meal appeared to reduce systemic exposure of tasurgratinib, however co‐administration with an acid‐reducing agent or a CYP3A inducer had a minimal impact on pharmacokinetics. [ABSTRACT FROM AUTHOR]

Probiotics and prebiotics have gained attention for their potential health benefits. However, their efficacy hinges on probiotic survival through the harsh gastrointestinal environment. Microencapsulation techniques provide a solution, with resistant starch (RS)-based techniques showing promise in maintaining probiotic viability. Specifically, RS-encapsulated probiotics significantly improved probiotic survival in gastric acid, bile salts, and simulated intestinal conditions. This study investigated the effects of a resistant-starch-encapsulated probiotic cocktail (RS-Pro) in the context of 5-fluorouracil (5-FU) chemotherapy, which frequently induces microbiota dysbiosis and intestinal mucositis. Female BALB/c mice were divided into three groups: a 5-FU group, a 5-FU+Pro group receiving free probiotics, and a 5-FU+RS-Pro group receiving RS-encapsulated probiotics. After 28 days of treatment, analyses were conducted on fecal microbiota, intestinal histology, peripheral blood cell counts, and body and organ weights. It was revealed by 16S rRNA MiSeq sequencing that 5-FU treatment disrupted gut microbiota composition, reduced microbial diversity, and caused dysbiosis. RS-Pro treatment restored microbial diversity and increased the population of beneficial bacteria, such as Muribaculaceae, which play roles in carbohydrate and polyphenol metabolism. Furthermore, 5-FU administration induced moderate intestinal mucositis, characterized by reduced cellularity and shortened villi. However, RS-Pro treatment attenuated 5-FU-induced intestinal damage, preserving villus length. Mild leukopenia observed in the 5-FU-treated mice was partially alleviated in 5-FU+Pro and 5-FU+RS-Pro groups. These findings suggest that RS-Pro may serve as an adjunct to chemotherapy, potentially reducing adverse effects and improving therapeutic outcomes in future clinical applications. [ABSTRACT FROM AUTHOR]

Copyright of Science & Technology of Food Industry is the property of Science & Technology of Food Industry Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Helicobacter pylori infection has significant epidemiological relevance due to the carcinogenic nature of this bacterium, which is potentially associated with cancer. When detected, it should ideally be eradicated using a treatment that currently involves a combination of gastric acid suppressors and multiple antibiotics. However, this treatment raises questions regarding efficacy and safety profiles in patients with specific comorbidities, including inflammatory bowel diseases (IBD). Eradication therapy for H. pylori includes components associated with adverse gastrointestinal events, such as Clostridioides difficile colitis. This necessitates quantifying this risk through dedicated studies to determine whether this antimicrobial treatment could be significantly associated with IBD relapse or exacerbation of pre-existing IBD, as well as whether it could potentially lead to the de novo onset of IBD. Although the available evidence is reassuring about the safety of eradication therapy in patients with IBD, it is limited, and there are no specific recommendations for this particular situation in the leading international IBD and H. pylori guidelines. Therefore, studies need to evaluate the efficacy and safety profiles of the available antimicrobial regimens for H. pylori eradication in patients with IBD, both in clinical trial settings and in real-life studies. [ABSTRACT FROM AUTHOR]

Neokestose is considered to have a prebiotic function. However, the physiological activity of neokestose remains unknown. Neokestose has a blastose, a sucrose analog, in its structure. We previously demonstrated that oral administration of blastose to diabetic rats suppressed the increase in plasma glucose (PG) concentration after sucrose administration. Therefore, neokestose might have a similar effect. In this study, we investigated the effects of neokestose on PG concentrations and the mechanism of its action. We first administered neokestose orally to streptozotocin-induced diabetic rats and observed that the expected consequent increase in PG concentration was significantly suppressed. Next, we examined the inhibitory effect of neokestose on glycosidase activity, but observed only a slight inhibitory effect. Therefore, we hypothesized that neokestose might be hydrolyzed by gastric acid to produce blastose. We performed an acid hydrolysis of neokestose using artificial gastric juice. After acid hydrolysis, peaks corresponding to neokestose and its decomposition products including blastose were observed. Therefore, we suggest that neokestose and blastose, a decomposition product, synergistically inhibit glycosidase activity. These findings support the potential use of neokestose as a useful functional oligosaccharide that can help manage plasma glucose concentrations in patients with diabetes mellitus. [ABSTRACT FROM AUTHOR]

Background: In the absence of Helicobacter pylori (HP) infection, a characteristic gastric mucus adhesion may appear during the use of vonoprazan. We named this novel characteristic mucus "web-like mucus" (WLM). This study aimed to determine the incidence and risk factors for WLM. Methods: Between January 2017 and January 2022, 5665 patients were enrolled in this study. The patients were divided into a proton-pump inhibitor (PPI)-prescribed group (n = 2000), a vonoprazan-prescribed group (n = 268), and a no-PPI/vonoprazan-prescribed (n = 3397) group, and the presence of WLM was examined. After excluding four patients with autoimmune gastritis, the remaining 264 patients in the vonoprazan group were divided into WLM and non-WLM groups, and their clinical features were analyzed. Results: A total of 55 (21%) patients had WLM, all in the vonoprazan-prescribed group. There were no significant differences in factors such as, sex, age, chronic kidney disease, diabetes mellitus, HP eradication history, smoking, or alcohol consumption between the WLM and non-WLM groups. The median duration from the start of vonoprazan administration to the endoscopic detection of WLM was 2 (1–24) months. Conclusions: WLM appears to be a characteristic feature in patients treated with vonoprazan. [ABSTRACT FROM AUTHOR]

Males and females have long shown disparities in body weight and height; yet, the underlying mechanisms influencing growth and development remain unclear. Male and female Zhedong White Geese (ZDW) geese have long been selected for large body size and egg production, respectively. This led to a large difference in body weight between males and females, making them a unique model for studying the effects of sex on growth and development. This study aimed to elucidate these mechanisms by comparing the transcriptomes of muscle and pituitary tissues in male and female ZDW geese to identify the critical genes responsible for the effects of sex on growth performance. Our analysis revealed 1101 differentially expressed genes (DEGs) in leg musculature (507 upregulated, 594 downregulated), 773 DEGs in breast musculature (311 upregulated, 462 downregulated), and 517 DEGs in the pituitary gland (281 upregulated, 236 downregulated) between male and female geese. These DEGs were significantly enriched in gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with endocrine metabolism (e.g., hormonal activities), muscle formation (e.g., sarcomere and myofibril), and bone formation (e.g., bone morphogenesis and cartilage formation). The upregulated genes in males were enriched in KEGG pathways involving nutrient digestion and absorption (vitamin and protein), as well as the secretion of digestive juices (gastric acid and bile). Through protein–protein interaction analyses, we also observed high-density gene networks related to muscle fiber development, calcium ion metabolism, mitochondrial respiratory chain, and bone development. Therefore, our multi-tissue transcriptome analysis provides a deeper understanding of the complex and systematic gender-driven effects on growth and development in geese. IGF1, GHRHR, and NCAPG-LCORL and pathways related to myogenesis might play vital roles in gender differences before hormones exert their effect. [ABSTRACT FROM AUTHOR]

This study investigates the dynamic fluctuations of pH caused by gastric acid secretion, a process of both biological and clinical significance, with microrobots. Abnormal patterns of acidity often indicate gastrointestinal diseases, underlying the importance of precise intragastric pH monitoring. Traditional methods using fluorescent probes face challenges due to their faint solid‐state fluorescence, limited target specificity, and accuracy. To overcome these obstacles, pH‐responsive fluorescent organic microparticles decorated with magnetite (Fe3O4) nanoparticles are engineered. These microrobots exhibit a unique fluorescence switching capability at a critical pH, enabling the monitoring of gastric acidity. The magnetic part of these microrobots ensures magnetic maneuverability to enable targeted navigation. The microrobots' fluorescence switching mechanism is elucidated through comprehensive spectroscopy, microscopy, and X‐ray diffraction analyses, revealing molecular‐level structural transformations upon interaction with gastric acid and antacids. These transformations, specifically protonation and deprotonation of the microrobots' fluorescent components, prompt a distinct fluorescence response correlating with pH shifts. In vitro and ex vivo experiments, simulating stomach conditions, confirm the microrobots' efficacy in pH‐responsive imaging. The results showcase the promising diagnostic potential of microrobots for gastrointestinal tract diseases, marking a significant advancement in imaging‐based medical diagnostics at targeted locations. [ABSTRACT FROM AUTHOR]

Copyright of Shipin Kexue/ Food Science is the property of Food Science Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Probiotics have many beneficial physiological activities, but the poor stability during storage and gastrointestinal digestion limits their application. Therefore, in this study, a novel type of shell–core microbead for loading probiotics was prepared through high-precision concentric drop formation technology using gelatin as the shell material and lipids as the core material. The microbeads have a regular spherical structure, uniform size, low moisture content (<4%) and high probiotic activity (>9.0 log CFU/g). Textural testing showed that the hardness of the medium-chain triglyceride microbeads (MCTBs), cocoa butter replacer microbeads (CBRBs) and hydrogenated palm oil microbeads (HPOBs) increased gradually (319.65, 623.54, 711.41 g), but their springiness decreased (67.7, 43.3, 34.0%). Importantly, lipids with higher melting points contributed to the enhanced stability of probiotics during simulated digestion and storage. The viable probiotic counts of the HCTBs, CBRBs and HPOBs after being stored at 25 °C for 12 months were 8.01, 8.44, and 8.51 log CFU/g, respectively. In the simulated in vitro digestion process, the HPOBs resisted the destructive effects of digestive enzymes and gastric acid on probiotics, with a reduction in the probiotic viability of less than 1.5 log CFU/g. This study can provide new ideas for the preparation of intestinal delivery probiotic foods. [ABSTRACT FROM AUTHOR]

Zastaprazan (JAQBO®) is a next-generation potassium-competitive acid blocker being developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, for the treatment of acid-related diseases. Zastaprazan binds directly to proton pumps in a competitive manner to reduce gastric acid secretion, allowing for a quick onset of action. On 24 April 2024, zastaprazan received approval in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). Zastaprazan is also undergoing phase III development for the treatment of gastric ulcer and for the prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer. This article summarizes the milestones in the development of zastaprazan leading to this first approval for erosive GERD. [ABSTRACT FROM AUTHOR]

Since the introduction of vonoprazan, a potassium-competitive acid blocker (P-CAB), it has been demonstrated to reversibly inhibit gastric acid secretion by engaging in potassium-competitive ionic binding to H+/K+-ATPase. In contrast, proton pump inhibitors (PPIs) achieve H+/K+-ATPase inhibition through covalent binding to cysteine residues of the proton pump. Reported cases have indicated an emerging trend of P-CAB-related gastropathies, similar to those associated with PPIs, as well as unique gastropathies specific to P-CAB use, such as the identification of web-like mucus. Pathologically, parietal cell profusions, which show a positively correlated with hypergastrinemia, have a higher incidence in P-CAB users compared to PPI users. Thus, this review aims to summarize the endoscopic and pathological findings reported to date concerning P-CAB-related gastric mucosal lesions. Additionally, it seeks to discuss the differences between the PPIs and P-CABs in terms of the formation and frequency of associated gastropathies. This review highlights the evident differences in the mechanism of action and potency of acid inhibition between P-CABs and PPIs, notably contributing to differences in the formation and frequency of associated gastropathies. It emphasizes the necessity to distinguish between P-CAB-related and PPI-related gastropathies in the clinical setting. [ABSTRACT FROM AUTHOR]

This study aims to develop innovative heterocyclic nanocomposites incorporating silver nanoparticles (SNPs) for potential therapeutic applications targeting infections, gastric ulceration, inflammation, and oxidative damage. By synthesizing new derivatives of spiro-thiazolidine-carbonitrile (Py-ST-X) and incorporating them into Ag nanoparticles (AgNPs) and carbon nanotubes (CNTs), we have prepared Ag@Py-ST-X and Ag@Py-ST-X@CNT nanocomposites, respectively. The physical properties of these materials were studied using XRD, TEM, SEM, and Zeta potential techniques. In our investigation involving rats with gastric ulcers, we observed noteworthy inhibitory effects on gastric acid enzyme activity, specifically H+/K+ATPase, by Ag@Py-ST-NO2 and Ag@Py-ST-Br nanocomposites, demonstrating reductions of 25 and 34%, respectively, compared to untreated ulcers. Nanotubulation of these compounds further improved their inhibitory efficacy to 29 and 45%, respectively. Additionally, these nanoparticles showed the most potent myeloperoxidase (MPO)-inhibitory activity, demonstrating 36 and 49% inhibition, respectively, with nanotubulated versions reaching 44 and 53%. Moreover, Ag@Py-ST-NO2@CNT and Ag@Py-ST-Br@CNT nanotubes showed significant antioxidant activity, reducing thiobarbituric acid reactive substances (TBARS) by 35 and 51%, and hydrogen peroxide (H2O2) levels by 49 and 71%, respectively. These therapeutic effects were confirmed by reductions in gastric surface area (GSA) by 44% and 52%, a decrease in ulcer index (UI) from 80% to 44 and 38%, and an increase in curative index (CI) from 19 to 55 and 62% following administration of Ag@Py-ST-NO2@CNT and Ag@Py-ST-Br@CNT, respectively. Histological studies support these findings, suggesting the potential of these nanocomposites as promising candidates for treating various disorders. [ABSTRACT FROM AUTHOR]

Background: Acid suppressant drugs (ASDs) are commonly used to decrease gastric acid production, but some evidence exists that ASDs exert immunomodulatory effects. Such an effect has not been investigated in dogs for which ASDs are routinely prescribed. Hypothesis: Compared to naïve subjects, dogs treated with ASDs will exhibit differences in leukocyte ratios after treatment. Animals: Fifty‐one dogs with mast cell tumors (MCTs). Materials and Methods: Dogs with MCT that were either AS naïve or treated with ASDs (i.e., histamine‐2‐receptor antagonists [H2RA] or proton pump inhibitors [PPI]) were included in this retrospective study. Subjects were categorized into 3 treatment groups (AS naïve, H2RA treated, and PPI treated), and leukocyte ratios (neutrophil:eosinophil, lymphocyte:monocyte, and neutrophil:lymphocyte [NLR]) were calculated before and after treatment. A mixed effects analysis of variance on ranks was used to assess differences in ratios between treatments, between pre‐ and post‐treatment time points, and between pre‐ and post‐time points for each treatment. Concurrent administration of antihistamines, corticosteroids, and chemotherapeutic drugs was assessed as a confounding factor. Results: Famotidine (n = 14/14) and omeprazole (n = 12/12) were the only H2RA and PPI used, respectively. Dogs receiving famotidine had a significant increase in median NLR from pre‐ to post‐treatment (3.429; range, 1.417–15 to 5.631; range, 2.654–92; P < 0.01) compared to PPI treated or AS naïve dogs. No differences existed in chemotherapeutic drug or corticosteroid use between groups. Conclusions: A significant difference in NLR was identified in famotidine treated dogs compared with omeprazole treated or AS naïve dogs. [ABSTRACT FROM AUTHOR]

S. boulardii, the probiotic variety of S. cerevisiae, is known for its different characteristics, even though the two strains share more than 99% genomic relatedness. Therefore, S. boulardii has been examined and evaluated for differential characteristics in many studies. This study aims to explain the differentiation of S. boulardii from well-identified S. cerevisiae strains by biochemical characteristics and the qPCR-HRM. Initially, S. cerevisiae isolates from the HUF Culture Collection, were screened for basic biochemical characteristics such as growth temperature, glucose, and galactose utilization tests. Out of all selected cultures, the viability at gastric pH was investigated by spectrophotometric readings. The results showed that one isolate was more resistant than other strains when exposed to gastric acids. After sequencing and phylogeny steps using LR0R universal primer, there was no significant differentiation for S. boulardii strains and therefore HRM analysis was performed to interrogate sequence variation and differentiate S. boulardii strains. HRM analysis has successfully distinguished even highly closely related yeast strains. [ABSTRACT FROM AUTHOR]

Amlapitta is among the most prevalent illnesses in the community. Every age group, every class, and every community experience it. The term "amlapitta corelated with hyperacidity" describes a group of symptoms brought on by an imbalance between the proximal intestine's and stomach's acid-secreting processes and the defences that keep them safe. Acid secreted by the stomach is typically necessary for digestion. Acidity is the term for the condition that arises when the stomach produces too much acid. Because amlapitta develops from the vitiation of Kapha Pitta Doshas, according to our Acharyas, it is treated by Pitta Shaman along with Vamana and Virechana. For the treatment of Amlapitta, Swamarg Chikitsta is described. In Ayurveda, Urdwarg Amplapitta, Vidagdhajeerna, Samapitta Lakshanas, and Pittaja Grahani Lakshana can all be used to explain hyperacidity. This indicates a reduction in symptoms including flatulence, nausea, indigestion, burning in the retrosternum, and acid reflux eructation.With particular reference to Dyspepsia or gastroesophageal reflux disease (GERD), Laghu Sutshekhar Rasa, Avipattikar Churna, and Patoladi kwatha, in conjunction with lifestyle and food change, offered significant improvement in Amlapitta symptoms. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate the effect of simulated gastric juice on surface roughness and flexural strength of three different CAD/CAM blocks. Materials and Methods: Resin based ceramic (RBC Group), High impact polymer composite (HIPC Group) and Zirconia (Z Group) as 3 groups were considered for the study (90 samples, 30 samples per group). In each group, 10 samples were evaluated without immersion in gastric juice (Baseline). Remaining 20 samples were immersed for total of 24 hours in simulated gastric juice (pH 1.2). The surface roughness and flexural strength of samples was evaluated at the end of 6 hours and 24 hours. This was repeated for all groups. The data obtained was subjected to One way and Multivariate ANOVA and Tukey HSD tests. The significance level was fixed at 5% (p<0.05) Results: One way ANOVA showed surface roughness of Z group decreased significantly after acid immersion whereas RBC group and HIPC group showed significant increase in the surface roughness after acid immersion. One way multivariate ANOVA revealed statistically significant differences between the groups. Tukey HSD revealed a significant difference from base line to 24 hours across all groups. The surface changes were not significant between 6 hours to 24 hours in Z (p=0.261), RBC (p=0.797), HIPC (p=0.401) and baseline to 6 hours in HIPC group (p=0.397). The flexural strength of all the groups decreased significantly after acid immersion. The change in flexural strength from baseline to 6 hours was not significant in RBC (p=0.123) and HIPC groups (p=0.126) and 6 hours to 24 hours in RBC group (p=0.096). Z group showed a significant reduction from baseline to 6, 6 to 24 and baseline to 24 hrs. RBC and HIPC showed significant reduction from baseline to 24 hrs; and HIPC from 6 to 24 hrs Conclusion: Resin based ceramic is a suitable material in terms of flexural strength and surface roughness in gastric acid regurgitation, followed by Zirconia as the surface roughness does not increase from the baseline. High impact polymer composite can be a suitable restorative material in severe abrasion and erosion cases as it is least affected by acid in terms of roughness. [ABSTRACT FROM AUTHOR]

This study aimed to investigate the effects of resveratrol concentrations (0–15%w/w), pH (3–9), and heating conditions (60–90 °C, 20 min) on the physicochemical properties, complexation rate, digestive characteristics, and polyphenol release of resveratrol-wheat/rice starch complexes. It was found that resveratrol decreased the swelling power (wheat starch from 8.62 to 8.29% and rice starch from 11.04 to 10.77% at 10% resveratrol) and transparency (wheat starch from 20.9 to 20.17% and rice starch from 17.17 to 12.2% at 10% resveratrol) of the two starches, and increased the solubility of wheat starch but decreased that of rice starch. Resveratrol at 10% achieved the highest complexation efficiency with wheat/rice starch, with complexation rates of 28.02% and 24.31%, respectively. The process conditions of medium alkaline (pH 7, pH 9) or high temperature (90 °C) were also favorable for the complexation of resveratrol with starch. Resveratrol significantly limited the digestion rate of rice starch and wheat starch (P < 0.05), and when the resveratrol addition was increased from 0 to 10%, the rapidly digestible starch of resveratrol-wheat starch and resveratrol-rice starch decreased by 11.33% and 15.34%, and the resistant starch was elevated by 12.54% and 7.59%. Moreover, the resveratrol-starch complex could effectively protect resveratrol, reduce the destruction by gastric acid, and delay the release of more resveratrol into the intestine (resveratrol-rice starch prepared at 10% resveratrol and 70 °C was able to reach 42.37%). Structural analyses showed that resveratrol and starch were mainly connected through hydrogen bonding and hydrophobic interactions. Overall, the results indicated that resveratrol has great prospects for regulating postprandial blood glucose levels following the consumption of starch foods and provides novel insights into the future development of functional starch foods. [ABSTRACT FROM AUTHOR]

Copyright of Revista Foco (Interdisciplinary Studies Journal) is the property of Revista Foco and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

• Tagetes erecta L. components (ray, disc florets, and oil) reduces the risk of ulcers. • Higher pH, reduced acidity, and lower ulcer index confirm herb's ulcer-protective effects. • Hydro-ethanolic extract showed significant dose dependent anti-ulcer potential. • Single oil dose reduces acute ulcers by 94 % and chronic ulcers by 96.93 %. • Prepared leaf oil surpasses herbal extract for superior ulcer protection. The Tagetes erecta Linn (family: Asteraceae) herb possesses medicinal and antioxidants value. The herb is traditionally used to treat various ailments, including ulcers. In order to investigate antiulcer activity of T. erecta herb , experimental study was performed between ray and disc florets extracted with 30 parts of water and 70 parts of ethanol solvents using Soxhlet apparatus and leaf's essential oil extracted in Clevenger apparatus by steam distillation method. Two doses of the hydroethanolic extract (400 and 800 mg/kg, Per os) and single dose of essential oil (10 ml/Kg, Per os) were administered for five consecutive days. Rat's pyloric ligation and aspirin (200 mg/kg, Per os) were used to induce acute and chronic gastric ulcers respectively. Antiulcer activity of both the herb's parts was compared on gastric juice parameters (pH, free acidity, total acidity) ulcer-index and ulcer percent protection. The p value of less than 0.05 was considered significant in statistical analysis. Elevation in pH, reduction in free acidity, total acidity and ulcer-index in both the ulcer models confirm that the test drug showed the ulcer-protective activity in rats. Dose-dependent effects were observed in the antiulcer activity of the hydroethanolic extract. However, the leaf's essential oil showed 94 % and 96.93 % ulcer protection in the pyloric ligation and aspirin-induced gastric ulcer models respectively. The hydroethanolic extract and the essential oil may be capable in part, regulating gastric acid secretion pathways or stimulating the cytoprotective secretion of bicarbonate, mucus and prostaglandins. Histological studies supported the observed antiulcer activity of the herb. The essential oil has more potent and significant anti-ulcer activity than hydro-ethanolic extract and respective standard drugs: ranitidine (50 mg/kg, Per os) & pantoprazole (20 mg/kg, Per os). The herb exhibits antiulcer activity, which could be due to the presence of lead phytochemicals: Quercetin-3-methyl ether, quercetin-7-methyl-ether & kaempferol flavonoids in the extract and limonene & terpinolene in leaf's essential oil and, thus, confirmed the traditional uses of T. erecta in the treatment of ulcers. The herb may cure acid pepsin disorders. [ABSTRACT FROM AUTHOR]

Gastric acid secretion is closely associated with the development and treatment of chronic gastritis, gastric ulcers, and reflux esophagitis. However, gastric acid secretion is affected by complex physiological and pathological factors, and real-time detection and control are complicated and expensive. A gastric delivery system for antacids and therapeutics in response to low pH in the stomach holds promise for smart and personalized treatment of stomach diseases. In this study, pH-responsive modular units were used to assemble various modular devices for self-regulation of pH and drug delivery to the stomach. The modular unit with a release window of 50 mm2 could respond to pH and self-regulate within 10 min, which is related to its downward floatation and internal gas production. The assembled devices could stably float downward in the medium and detach sequentially at specific times. The assembled devices loaded with antacids exhibited smart pH self-regulation under complex physiological and pathological conditions. In addition, the assembled devices loaded with antacids and acid suppressors could multi-pulse or prolong drug release after rapid neutralization of gastric acid. Compared with traditional coating technology, 3D printing can print the shell layer by layer, flexibly adjust the internal and external structure and composition, and assemble it into a multi-level drug release system. Compared with traditional coating, 3D-printed shells have the advantage of the flexible adjustment of internal and external structure and composition, and are easy to assemble into a complex drug delivery system. This provides a universal and flexible strategy for the personalized treatment of diseases with abnormal gastric acid secretion, especially for delivering acid-unstable drugs. [ABSTRACT FROM AUTHOR]